| SEC For   |   |  |   |   |  |  |  |      |  |                    |  |  |  |  |  |  |  |
|---|---|--|---|---|--|--|--|------|--|--------------------|--|--|--|--|--|--|--|
| FORM 4 UNITED   |   |  |   | D STATES SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549 |  |  |  |      |  |                    |  |  |  |  | OMB APPROVAL   |  |  |
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See |   |  |   |   |  |  | NT OF CHANGES IN BENEFICIAL OWNERSHIP  |      |  |                    |  |  |  |  | OMB Number: 3235-0287<br>Estimated average burden<br>hours per response: 0.5 |  |  |
|   | tion 1(b).  |  |   | File  | ed purs<br>or  | pursuant to Section 16(a) of the Securities Exchange Act of 1934<br>or Section 30(h) of the Investment Company Act of 1940 |  |      |  |                    |  |  |  | Lindis p   |  | 0.5  |  |
| 1. Name and Address of Reporting Person <sup>*</sup><br><u>PAIGE CHRISTOPHER</u>                  |   |  |   |   |  | 2. Issuer Name and Ticker or Trading Symbol <u>AVROBIO</u> , Inc. [ AVRO ]   |  |      |  |                    |  |  | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>X Director 10% Owner |  |  |  |  |
| (Last) (First) (Middle)<br>C/O AVROBIO, INC.  |   |  |   |   | 3. Date of Earliest Transaction (Month/Day/Year)<br>06/08/2022 |  |  |      |  |                    |  |  | Officer (give title Other (specify below) below)   |  |  |  |  |
| ONE KENDALL SQUARE, BLDG. 300, SUITE  |   |  |   | ГЕ <b>2</b> 01  | 4. If Amendment, Date of Original Filed (Month/Day/Year)       |  |  |      |  |                    |  |  | 6. Individual or Joint/Group Filing (Check Applicable Line)  |  |  |  |  |
| (Street)<br>CAMBRIDGE MA 02139  |   |  |   |   |  | X Form fil   |  |      |  |                    |  |  |  |  | led by One Reporting Person<br>led by More than One Reporting                |  |  |
| (City)  |   |  |   |   |  |  |  |      |  |                    |  |  |  |  |  |  |  |
|   |   | Tab  | le I - Nor  | n-Deriv   | ativ   | e Se   | curities   | s Ac | quired, D  | isposed o          | of, or Be  | neficial                               | y Owned  | l  |  |  |  |
| 1. Title of Security (Instr. 3)<br>2. Transa<br>Date<br>(Month/D                                  |   |  |   |   |  | Execution Da   |  |      | Code (Ins  |                    |  | ed (A) or<br>tr. 3, 4 and              | Beneficia<br>Owned F   | es I<br>ally (<br>Following (  | 6. Ownership<br>Form: Direct<br>D) or Indirect<br>I) (Instr. 4)              | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership                |  |
|   |   |  |   |   |  |  |  |      | Code V   | Amount             | (A) or<br>(D)  | Price                                  | Reported<br>Transact<br>(Instr. 3 a  | ion(s)   |  | (Instr. 4)   |  |
|   |   | -  |   |   |  |  |  |      | uired, Dis<br>s, options,                                      | •                  | •  |  | Owned  |  |  |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)   | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution I<br>if any<br>(Month/Day | Date,   | 4.<br>Transa<br>Code (<br>3)                                   |  | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D) (Instr.<br>3, 4 and 5) |      | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amoun<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)  | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | Ownershi<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4              | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|   |   |  |   |   | Code   | v  | (A)  | (D)  | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of<br>Shares |  |  |  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)  | \$1.06  | 06/08/2022                                 |   |   | Α  |  | 17,478   |      | (1)  | 06/07/2032         | Common<br>Stock  | 17,478                                 | \$0  | 17,478   | D  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)  | \$1.06  | 06/08/2022                                 |   |   | Α  |  | 17,478   |      | (1)  | 06/07/2032         | Common<br>Stock  | 17,478                                 | \$0  | 17,478   | D  |  |  |

Explanation of Responses:

1. The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

/s/ Christopher Gerry, Attorney 06/10/2022

in Fact for Christopher Paige

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.